Clinical study on Qinxiang Qingjie Oral Liquid combined with oseltamivir in treatment of upper respiratory tract infections in children
Objective To explore the clinical efficacy of Qinxiang Qingjie Oral Liquid combined with Oseltamivir Phosphate Granules in treatment of upper respiratory tract infections in children.Methods Children(124 cases)with upper respiratory tract infections in Jiangnan Campus of the Sixth Affiliated Hospital of Harbin Medical University from June 2021 to June 2022 were divided into the control group(62 cases)and the treatment group(62 cases)using the random number table method.Children in the control group were po administered with Oseltamivir Phosphate Granules,weight≤15 kg,30 mg;23 kg≥weight>15 kg,45 mg;40 kg≥weight>23 kg,60 mg;weight>40 kg,75 mg;twice daily.Children in the treatment group were po administered with Qinxiang Qingjie Oral Liquid on the basis of the control group,3—7 years old,10 mL/time;7—14 years old,15 mL/time;three times daily.Children in two groups were treated for 1 week.The clinical efficacies,the clinical symptoms,and inflammatory factor indicators in two groups were compared.Results After treatment,the total effective rate of the treatment group was 91.94%,which was higher than 79.03%of the control group(P<0.05).Compared with the control group,the disappearance time of sore throat,fever,runny nose,lung rales,cough,and fatigue in the treatment group was shorter(P<0.05).After treatment,the serum levels of CRP,IL-1β,SIL-2R,and SAA in two groups were decreased,but the serum levels of IFN-γ in two groups were increased(P<0.05).Compared with the control group,the levels of CRP,IL-1β,SIL-2R,and SAA in the treatment group were lower,but the levels of IFN-γ were higher(P<0.05).Conclusion Qinxiang Qingjie Oral Liquid combined with Oseltamivir Phosphate Granules can be used to treat upper respiratory tract infections in children,improve the body's immunity,and improve the serum inflammatory factor levels in children.
NETL
NSTL
万方数据
